Baricitinib
also Olumiant
- Approved (Olumiant) · oral · Eli Lilly · FDA approved · EMA approved · Severe alopecia areata only
JAK inhibitor pill used for severe alopecia areata
Baricitinib, sold under the brand name Olumiant among others, is an immunomodulatory medication used for the treatment of rheumatoid arthritis, alopecia areata, and COVID-19. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.
Read “Baricitinib” on Wikipedia and its adverse effects · text from Wikipedia, CC BY-SA 4.0
Information, not medical advice. Talk to a licensed doctor or pharmacist before starting or changing a treatment.
Research 10
- Oral Baricitinib Restores Hair Loss in Alopecia Areata
- Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure
- Baricitinib-loaded EVs promote alopecia areata mouse hair regrowth by reducing JAK-STAT-mediated inflammation and promoting hair follicle regeneration
- Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
- Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata
- Baricitinib: From Rheumatoid Arthritis to COVID‐19
- There are early, gradual and late responders for scalp hair regrowth in patients with alopecia areata treated with baricitinib
- Application of Baricitinib in Dermatology
- Beard hair response in alopecia areata universalis treated with baricitinib
- Hair regrowth in a patient with central centrifugal cicatricial alopecia after a 2-month trial of baricitinib
- When JAK Selectivity Matters: Worsening Urticaria and Recurrent Allergic Rhinitis After Switching From Baricitinib to Ritlecitinib in Alopecia Areata
- Baricitinib response pattern by baseline nail involvement in children under 12 with alopecia areata
- Comparative Efficacy of Ritlecitinib, Baricitinib, and Upadacitinib in Adolescents With Severe Alopecia Areata: A Bayesian Network Meta‑Analysis
- Real-World Safety of Janus Kinase Inhibitors in Alopecia Areata: A Propensity Score-Matched Cohort Study of a Global Federated Health Network
- Janus kinase inhibitors in the management of lichen planus: a systematic review
- Baricitinib Efficacy Through 4 Years in Responders and Safety up to 5 Years in Adults with Severe Alopecia Areata: Final Results from BRAVE-AA1 and BRAVE-AA2
- Monitoring the Response to JAK Inhibitor Treatment in Alopecia Areata Using Reflectance Confocal Microscopy and Videotrichoscopy: A 60-Week Observational Study
- Impact of baricitinib on thyroid function and autoimmunity in severe alopecia areata: A pilot study
- Synergistic chitosan nanoparticles loaded with baricitinib for the management of persistent chemotherapy-induced alopecia
- Treatment of concomitant alopecia areata and systemic lupus erythematosus with ivarmacitinib: a case report and literature review
Posts 11
- Hair Loss Inflammation Prevention Stack
- Baricitinib (Olumiant) - alopecia cured
- Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks
- Olumiant active ingredient Baricitinib
- ALRV5XR - what have anybody heard of it?What is that compound?
- Scalp biopsy results came back and I'm diagnosed with alopecia areata
- An arthritis drug that can be used for Alopecia.
- Olumiant alternative for Alopecia Areata?
- Anyone heard of or have experience using baricitinib?
- Most promising cures for baldness as of May 2026
- Which 2026 hair‑loss treatments have the strongest evidence so far? (minoxidil/finasteride vs. clascoterone, PP405, Re:You’s NV‑623/624, AMP‑303, RU58841)